Digene Corporation engages in the development, manufacture, and marketing of its proprietary gene-based diagnostic tests for the screening, monitoring, and diagnosis of human diseases with a focus on women’s cancers and infectious diseases worldwide. The company primarily offers human papillomavirus (HPV) testing products, which are FDA-approved tests for the detection of HPV, are a reproducible, objective test for the primary cause of cervical cancer. Its primary product is The Digene HPV Test, a FDA-approved test for HPV, the primary cause of cervical cancer. The company also provides a diagnostic test products portfolio that includes gene-based tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses and hepatitis B virus. In addition, it develops and sells to clinical laboratories the equipment, instrumentation, and accessories used to perform clinical specimen testing with its diagnostic tests. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. As of July 23, 2007, Digene Corp. is a subsidiary of QIAGEN N.V.